Mark Sebastian Sulkowski MD

Professor of Medicine, Johns Hopkins University School of Medicine; Senior Associate Dean for Clinical Trials; Director Division of Infectious Diseases, Johns Hopkins Bayview Medical Center; Medical Director, Viral Hepatitis Center

Join to View Full Profile

10751 Falls RoadFalls Concourse Ste 412Lutherville, MD 21093
Phone+1 410-583-2900
Fax+1 410-583-2654

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1995 - 1998
Duke University HospitalResidency, Internal Medicine, 1992 - 1995
Lewis Katz School of Medicine at Temple UniversityClass of 1992

Certifications & Licensure

MD State Medical License 1996 - 2025
NC State Medical License 1994 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2011

Clinical Trials

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
Completed
Not Applicable
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Completed
Phase 3
Management of Hepatitis C in HIV-Infected and Uninfected IDUs Start of enrollment: 2004 Jan 01
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Start of enrollment: 2007 Jul 01
Completed
Phase 1
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults Start of enrollment: 2010 Sep 01
Completed
Phase 1
Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) Start of enrollment: 2021 Mar 31
Completed
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
HBV-HIV Coinfection Research Network Start of enrollment: 2014 Apr 01
Completed
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy Start of enrollment: 2015 Sep 16
Terminated
Phase 2
deLIVER: Direct Acting Antiviral Effects on the Liver Start of enrollment: 2017 Jan 01
Completed
Phase 4
Rapid HCV Treatment Access for Persons Who Use Drugs Start of enrollment: 2021 Aug 06
COMPLETED
NA
Join now to see all

Publications & Presentations

PubMed

New potent HBV replication inhibitors for the management of chronic hepatitis B are needed.
Timothy M Block, Ju-Tao Guo, Fabien Zoulim, Charles M Rice, Chloe L Thio
Nature Reviews. Gastroenterology & Hepatology. 2025-03-01
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.
Thiago S Torres, Pooja T Saha, Laura Smeaton, Chanelle Wimbish, Dimas Alexandre Kliemann
Quality of Life Research. 2025-02-28
Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment.
Maraake Taddese, Tanner Grudda, Giulia Belluccini, Mark Anderson, Gavin Cloherty
The Journal of Clinical Investigation. 2025-01-30

Journal Articles

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-Infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study
Mandana Khalili, Mark Sulkowski, Marc G Ghany, Richard K Sterling, Raymond T Chung, David E Kleiner, Mamta K Jain, Nature

Lectures

Hepatitis C Management: State of the Art 2013
Hepatitis C Management, New York, New York - 5/9/2013
Hepatobiliary Disease in Clinical Practice: Update XX
University of Miami, Miami, Florida - 2/22/2013

Press Mentions

Biden: ‘Every American Can Do Their Part’ to Eliminate Viral Hepatitis Epidemic in USMay 20th, 2023
HCV Elimination Represents ‘Win-Win-Win’ for Patients, Public Health, Cost SavingsMarch 20th, 2023
Flu Season Returns Amid COVID-19 Pandemic: Johns Hopkins Medicine Experts AvailableSeptember 27th, 2021
Join now to see all